





#### **ERA-EDTA COUNCIL**

#### President

Andrzej Więcek, Poland

#### Secretary-Treasurer

Jonathan G. Fox, United Kingdom

#### Chairperson of the Administrative Offices

Markus Ketteler, Germany

#### Editor-in-Chief

of "Nephrology Dialysis Transplantation"

Carmine Zoccali, Italy

#### Chairperson of the Registry

Ziad Massy, France

#### **Ordinary Council Members**

Mustafa Arici, Turkey

Angel Argiles Ciscart, France

Pieter Evenepoel, Belgium

Danilo Fliser, Germany

Michel Jadoul, Belgium

Gert Mayer, Austria

Jolanta Malyszko, Poland

Alberto Ortiz, Spain

#### **Congress Presidents**

Gert Mayer, Austria

Andrzej Więcek, Poland

#### www.era-edta.org

#### ÖGN COUNCIL

#### President

Karl Lhotta, Feldkirch

#### Vice President

Alexander Rosenkranz, Graz

#### **Secretary**

Emanuel Zitt, Feldkirch

#### Secretary Treasurer

Andreas Vychytil, Vienna


#### **Council Members**

Renate Klauser-Braun, Vienna Rainer Oberbauer, Vienna Marcus Saemann, Vienna

www.niere-hochdruck.at







Leading European Nephrology









ONGRESS
VIENNA MAY 21"-24", 2016
AUSTRIA

#### Invitation



Dear Colleagues and Friends;


It is a great pleasure and honour for us to invite you to Vienna to attend the 53rd ERA-EDTA Congress in 2016, which will be held in cooperation with the Austrian Society of Nephrology. In addition many other societies with similar interests will join us as well. In line with a long standing tradition the scientific programme committee, this time chaired by Prof. Danilo Fliser from Homburg/Saar (Germany), is working hard to make this event again a memorable one by complementing up to date research sessions with diverse educational symposia. The Austria Center Vienna, the congress venue, can be reached conveniently from the historic city center (Stephansplatz) within 7 minutes by underground transportation. It is located within a few minutes' walk from the river Danube and the Donaupark, a popular leisure area, and it has the capacity to host 20.000 delegates. It offers 24 fully equipped lecture rooms, 180 meeting rooms and 22.000 sqm of exhibition space.

Vienna is a modern city in the heart of Europe, which nonetheless was able to preserve its historic charm. Located near the city center one of the most famous buildings is the Vienna Secession built by Joseph Maria Olbrich, the dome of which can be seen on the front page of this announcement. The Vienna Secession was formed in 1897 by a group of artists (among them Gustav Klimt, Kolomann Moser and Josef Hoffmann), who had resigned from the Association of Austrian Artists because of the prevailing conservatism. Above the entrance visitors can read "To every age its art. To art its freedom", which symbolizes the Secessionists´ desire to explore the possibilities of art outside the confines of tradition. The main theme of the Congress "From big data to personalized therapy – biostatistics meets molecular medicine" somehow mirrors this effort. The Vienna congress will focus on new ways on how research methodologies might change in the near future and why Nephrology is on the top list of areas that can benefit from these developments.

We all hope that you will join us at this event and share some great days of education and science but also use your visit to enjoy one of the most beautiful cities located in the heart of Europe.

Gert Mayer 53<sup>rd</sup> Congress President **Andrzej Więcek** ERA-EDTA President Danilo Fliser
Chair of the Scientific Committee





#### Scientific Committee

#### **CONGRESS PRESIDENTS**

Gert Mayer, Austria Andrzej Więcek, Poland

#### **CONGRESS SECRETARY**

Alexander Rosenkranz, Austria

#### **SCIENTIFIC COMMITTEE**

Chair: Danilo Fliser, Germany

Kerstin Amann, Germany Rosanna Coppo, Italy Olivier Devuyst, Switzerland Kathrin Eller, Austria Jürgen Floege, Germany Denis Fouque, France

(also Chairperson of the Paper Selection Committee)

Hallvard Holdaas, Norway Faiçal Jarraya, Tunisia Marian Klinger, Poland

Mariusz Kusztal, Poland

Francesca Mallamaci, Italy Ziad Massy, France

Gert Mayer, Austria

Alberto Ortiz, Spain

Ton Rabelink, Netherlands

Marcus Saemann, Austria Mehmet Sukru Sever, Turkey

Rukshana Shroff, United Kingdom

Peter Stenvinkel, Sweden

Nicholas Topley, United Kingdom Wim Van Biesen, Belgium

#### **Important Addresses**



#### **SCIENTIFIC PROGRAMME**

#### **Congress Presidents**

#### **ERA-EDTA President**

Andrzej Więcek
Department of Nephrology,
Transplantation and Internal Medicine
Medical University of Silesia in Katowice
Francuska 20-24
PL-40-027 Katowice - Poland
Fax: +48-32-2553726
E-mail: awiecek.president@era-edta.org

#### **Congress President**

Gert Mayer
Department of Internal Medicine IV
(Nephrology and Hypertension)
Medical University Innsbruck
Anichstrasse 35 A - 6020 Innsbruck - Austria
Fax: +43-512-50425857
E-mail: gert.mayer@i-med.ac.at

#### ÖGN President

Karl Lhotta
Dept. of Nephrology and Dialysis
Landeskrankenhaus Feldkirch
6800 Feldkirch - Austria
Fax: +43-5522-3037506
E-mail: karl.lhotta@lkhf.at

#### **Congress Secretary**

Alexander Rosenkranz
Medical University Graz
Department of Internal Medicine
Clinical Division of Nephrology
Auenbruggerplatz 27
8036 Graz - Austria
Fax: +43-316-38514426
alexander.rosenkranz@medunigraz.at

#### **Chair of the Scientific Committee**

Danilo Fliser Saarland University Medical Centre Dept. Internal Medicine IV D-66424 Homburg/Saar - Germany Fax: +49-6841-1623540 E-mail: indfli@uks.eu

#### **CONGRESS SECRETARIAT**

#### **ERA-EDTA Congress Office**

Via XXIV Maggio 38 I-43123 Parma - Italy Phone: +39-0521-989078 Fax: +39-0521-959242

#### Registrations

E-mail: registrations@era-edta.org Phone: +39-345-0211784 Fax: +39-0521-959242

# **Exhibition and Sponsorship Sales Contact**

Mr. Paolo Zavalloni ERA-EDTA Congress Office Phone: +39-345-4592758 Fax: +39-051-309477 Skype: PaoZav E-mail: zavalloni@era-edta.org

#### **ERA-EDTA Membership Office**

Via XXIV Maggio 38
I-43123 Parma - Italy
Phone: +39-344-1409706
Fax: +39-0521-959242
E-mail: membership@era-edta.org
www.era-edta.org

#### ÖGN Secretariat

E-mail: oegn@vlkh.net

#### **Official Housing Agent**



C-IN

5. kvetna 65

140 21 Prague 4 - Czech Republic Phone: +420 261 174 301 Fax: +420 261 174 307

E-mail: hotels.eraedta2016@c-in.eu





#### Held jointly with Österreichische Gesellschaft für Nephrologie

### **Congress Timetable**

Leading European Nephrology

Fluids and electrolytes, tubular transport, physiology
Hereditary disorders, development, pregnancy, paediatric nephrology
Glomerular diseases and general clinical nephrology
Chronic Kidney Disease: pathophysiology,
epidemiology, prevention, progression, aging

End Stage Renal Disease and dialysis Home therapies, peritoneal dialysis Transplantation and immunology Hypertension, diabetes, vascular diseases Acute Kidney Injury and intensive care nephrology

epidemiology, prevention, progression, aging									
9.00 - 12.15 (coffee break 10.30 - 10.45)	CME 1 IWG - News in the diagnostics and treatment of	CME 2 DESCARTES WG - Practical issues in kidney transplan-	CME 3 EURECA-m WG - A preview of the future in cardiovascular risk	- the new standard	CME 5 DIABESITY WG - Diabetes and obesity in renal	grow old - nutritiona considerations for th	l mia: is it only a toxin affair? The emerging	CME 8 WGI disorders: the k	KD - Inherited idney and beyond
	glomerular disease	tation	management in CKD	of care?	disease	CKD elderly patient	concept of networking	3	
12.15 - 13.15 13.15 - 15.15	CME 9 -	CME 10 CKD-MBD	CME 11 EuroPD -	CME 12 - Disasters and the Nephrologist	CME 13 - Amyloido sis – old problem, new issues			Exercise as part o	iption for health – f nephrological care DRECKD)
15.15 - 15.30	Rheumatology for	WG - New insights	Peritoneal dialysis in			Break		·	,
15.30 - 17.30	nephrologists (13.15-16.30)	into CKD-MBD (13.15-16.30)	2016 - where do we stand? (13.15-16.30)	CME 17 - Non-pharma- cological treatment of resistant hypertension - consensus 2016	CME 18 - Less is mor why 'treating to target does not improve ou come of CKD patient	lithiasis and CKD		CME 21 - 1	Oxicology for rologists
18.00-19.30					elcome Ceremony	••			
					Exhibition				
19.30 - 21.00				W	elcome Reception				
				SUNDAY M	AV 22 2016				
08.00 - 09.30	S 01 - Membranous ne ropathy: new insight		Registry	S 04 - Aging and CKD S 0	5 - When cell iology meets ular transport ex		Mineral polism		MC 01 - Managing PD patients - from basic princi- ples to advanced practice
09.30 - 10.45			Poster	session, coffee break and e	xhibition visit			ÖGN	
10.45 - 11.30	PL 1 A. Kasarskis - A netwo oriented view of living syste to complement the reductio	ems			Publican state			Registry + General Assembly	
11.30 - 11.45	1 7 7		S 08 - Should PD as		Exhibition visit				
11.45 - 13.15	S 06 - LBCT	S 07 - Fluid management in the ICU	initial dialysis mo- dality become the standard of care?	cardiomyonathy			Diabetes mental FC 05 - C physiopath		
13.15 - 15.15					ndustry symposia				
15.15 - 16.45	S 11 - ASN Highlight	S 12 - The Lancet / Diabetes and Endo- crinology - Research	issues in kidney t	14 - Dialysis and ransplantation in children	mia	management care nep	Critical FC 09 - Dia phrology epidemio		
16.45 - 17.00					break and exhibition visi	it			
17.00 - 18.30	S 15 - ERA-EDTA & ES	S 16 - Nutrition in CKD patients	S 17 - Immunol- ogy and the kidney	calcium and PTH ation			Paediatric ology 1	FC 12 - History of nephrology	
				MONDAY M	AY 23 2016				
08.00 - 09.30	S 20 - How to handle the sensitized kidney transplant recipient	S 21 - Calcification and calciphylaxis	S 22 - PD clinical science	S 23 - Cross-talk between kidneys and other organs in AKI	S 24 - Development and pregnancy	FC 13 - Cell signal- ling 1	FC 14 - Hypertension experimental		
09.30 - 10.45			Poster session, coffee bre	ak and exhibition visit		,	ERA-EDTA General Assembly		1
10.45 - 11.30 11.30 - 11.45	PL 2 N. Schork - Is it tim for one-person trials?	ne			Exhibition visit				
11.45 - 13.15	S 25 - Improving treatmen of patients with CKD (ERA-EDTA & ISN)	S 26 - The Lancet / Diabetes and Endo- crinology - Review			S 29 - Sensing mechanisms in nephrology	FC 15 - Cardiovascular complications 1	FC 16 - PD	FC 17 - Transplantation clinical 2	FC 18 - CDK progression
13.15 - 15.15				In	dustry symposia				
	\$ 30 - The gut-renal axi	S 31 - ERA-EDTA & JSN	S 32 - DGF: how to prevent it?	\$ 33 - AKI - pathophysiology & definition	CDK epidemiology	FC 20 - Vascular access	FC 21 - Glomeru- lonephritis 1	FC 22 - Cell signalling 2	
16.45 - 17.00		0.25 14 1 3	0.26 D 1.61		reak and exhibition visi			FO 26	
17.00 - 18.30	S 34 - DOPPS	S 35 - Whole Person Care in Nephrology	S 36 - Renal fibrosis new insights	S 37 - Lipids in nephrology	FC 23 - Inflamma- tion & regeneration	FC 24 - Hyperten- sion clinical	FC 25 - Genetics	FC 26 - CKD rehabilitation	1
				, , , ,					
08.00 - 09.30	S 38 - Novel oral anti warfarin in C		The living kidney donor	ERA-EDTA & ESPN	341 - Kidney in systemi inflammatory diseases	scientific research	FC 27 - Nutrition		FC 28 - AKI experimental
09.30 - 09.45	DI 2 V Wood Transala	atation tolorance		Coffee b	reak and exhibition visi	J			
09.45 - 10.30	PL 3 K. Wood - Transplan can it turn into a	a reality?							
10.30 - 10.45					Exhibition visit				
10.45 - 12.15	S 43 - ERA-EDTA	A & ESH vascul		mones abnormalities in CKD patients	46 - Obesity and fat tissu - what is new and what is elevant for nephrologists	S 47 - NDT polar vie	FC 29 - Dialysis techniques	FC 30 - Diabetes clinical	
12.15 - 13.15					dustry symposia	0.74 11			
13.15 - 14.45	S 48 - Management o elderly with	CKD me.	nt in PD (ISPD)	esented by the nephrolo-	51 - What precipitate IgAN and what is the target for treatment?			FC 32 - Nephrolithiasis	
14.45 - 16.15	S 53 - Personalize	ed dialysis aspec	Special technological ts of ICU nephrology tracorporeal treatment	5 - Salt on the table	S 56 - Gone with the Wnt	FC 33 - Cardiovascul complications 2	ar FC 34 - Glomeru- lonephritis 2		FC 35 - Paediatric nephrology 2



Leading European Nephrology

#### **OPENING LECTURES**

Health policy making from the prospective of the **European Community** Karen Kadenbach, Austria, Vienna

From costs of kidney disease to a healthier society Raymond Vanholder, Ghent, Belgium

#### PLENARY LECTURES

A network-oriented view of living systems to complement the reductionist Andrew Kasarskis, New York, U.S.A.

Is it time for one-person trials? Nicholas Schork, La Jolla, U.S.A.

Transplantation tolerance: can it turn into a reality? Kathryn Wood, Oxford, United Kingdom

#### **MINI LECTURES**

The endothelial surface layer and the development of glomerular disease Ton J. Rabelink, Leiden, The Netherlands

Fundamental mechanisms of osmosis - revisited Johann Morelle, Brussels, Belgium

Inflammation, immunity and hypertension Ulrich O. Wenzel, Hamburg, Germany

How to improve HD outcome in children: more convection, more time, more sessions? Michel Fischbach, Strasbourg, France

Genetic testing in Steroid Resistant Nephrotic Syndrome Moin Saleem, Bristol, United Kingdom

Role of stem cells in kidney regeneration Michal Chmielewski, Gdansk, Poland

The value of kidney biopsy for the choice of therapy in patients with chronic GN Loreto Gesualdo, Bari, Italy

Anti PLA2R antibodies and outcome of membranous nephropathy Elion Hoxha, Hamburg, Germany

Guidelines in nephrology: what was expected? What was achieved?

Garabed Eknoyan, Houston, U.S.A.

How to prescribe Metformin in CKD Marc E. De Broe, Antwerp, Belgium

Potential anti-ageing interventions in CKD Peter Stenvinkel, Stockholm, Sweden

Blood pressure management in patients with CKD Ivan Rychlik, Prague, Čzech Republic

Vitamin D for better survival in CKD - any evidence? David Goldsmith, London, United Kingdom

Uremic toxins - how far did we come in 2016? Angel Argiles Ciscart, Montpellier, France

How valid are surrogate endpoints in nephrology research?

Carmine Zoccali, Reggio Calabria, Italy

Cardiovascular complications in CKD patients what we have learned during the last 10 years? Petar Kes, Zagreb, Croatia

Interventions to reduce progression of CKD - what is the evidence? John Feehally, Leicester, United Kingdom

The emerging role for bone alkaline phosphatase isoforms in chronic kidney disease - mineral and bone disorder Mathias Haarhaus, Stockholm, Sweden

Does calcium dialysate matter? Ercan Ok, Izmir, Turkey

Haemodynamic modifications induced by dialysis vascular access Carlo Basile, Taranto, Italy

New options for dialysis in neonates Claudio Ronco, Vicenza, Italy

Peritoneal dialysis - what is new in 2016? Monika Lichodziejewska-Niemierko, Gdansk, Poland

Mesenchymal stem cells as a potential pretransplant desensitization tool Gamal Saadi, Cairo, Egypt

Challenges of transplant rejection diagnosis Kerstin Amann, Erlangen, Germany

Blood pressure variability and the kidney Mustafa Arici, Ankara, Turkey

Clinical studies that target inflammation in diabetic nephropathy Peter Rossing, Gentofte, Denmark

Pathogenesis and treatment of HFPEF in CKD Loek van Heerebeek, Amsterdam, The Netherlands



Leading European Nephrology

Management of hyponatremia - what do the guidelines say? Goce Spasovski, Skopje, F.Y.R. of Macedonia

Antonino D'Antona and the first description in 1909 of the crush syndrome with renal failure after the Messina earthquake

Natale Gaspare De Santo, Naples, Italy In collaboration with the International Association for the History of Nephrology (IAHN)

#### **SYMPOSIA**

#### Track 1 Fluid and electrolytes, tubular transport, physiology

#### Track 1 Fluid and electrolytes, tubular transport, physiology

When cell biology meets tubular transport

mTOR and autophagy in tubular health and injury

**Tobias Huber**, Freiburg, Germany The endolysosomal system in the proximal tubule Olivier Dévuyst, Zurich, Switzerland

Regulation of sodium channel trafficking Olivier Staub, Lausanne, Switzerland

Cell biology of collecting duct water transport Robert Fenton, Aarhus, Denmark

#### Sensing mechanisms in nephrology

Calcium-sensing in the kidney Pascal Houillier, Paris, France

- Phosphate

J. Mariano Rodriguez, Cordoba, Spain

Renal and extrarenal sensing of acid-base Carsten Wagner, Zurich, Switzerland

Potassium David Ellison, Portland, U.S.A.

#### Hypoxia in kidney disease: integrating pre-clinical with clinical research

Oxygen sensing in the kidney Volker H. Haase, Nashville, U.S.A.

Development of novel drugs targeting renal hypoxia and anaemia

Masaomi Nangaku, Tokyo, Japan

Imaging oxygen metabolism: from animal to human studies

Christoffer Laustsen, Aarhus, Denmark

MRI paradigms to assess renal haemodynamics and oxygenation in human studies Speaker to be confirmed

#### Track 2

Hereditary disorders, development, pregnancy, paediatric nephrology

#### Actualities in hereditary disorders

ADPKD in children: new perspectives Francesco Emma, Rome, Îtaly

Genetic testing for rare disorders: practical steps Nine V.A.M. Knoers, Utrecht, The Netherlands

Inherited tubulopathies Olivier Devuyst, Zurich, Switzerland

Ciliopathies and cystic disorders Carsten Bergmann, Ingelheim Am Rhein, Germany

#### Dialysis and transplantation in children

Optimising BP control in CKD and dialysis patients Fabio Paglialonga, Milan, Italy

What have we learnt from peritoneal membrane biopsies: bench to bedside

Claus Peter Schmitt, Heidelberg, Germany

CKD-MBD in children: is bone disease the heart of the problem? Rukshana Shroff, London, United Kingdom

Corticosteroid-free kidney transplantation Ryszard Grenda, Warsaw, Poland

#### Development and pregnancy

- CAKÚT

Speaker to be confirmed

Renal progenitor cells to model inherited disorders Paola Romagnani, Florence, Italy

- Immunisation in pregnancy leads to membranous nephropathy

Pierre Ronco, Paris, France

- Pathophysiology of pre-eclampsia Matthew Hall, Nottingham, United Kingdom

#### Track 3 Glomerular diseases and general clinical nephrology

#### • Kidney in systemic inflammatory diseases

- B cell cytokine blockade in SLE David Jayne, Cambridge, United Kingdom

New and old auto-antibodies for lupus nephritis

Gian Marco Ghiggeri, Genoa, Italy Biologic drugs in the treatment of vasculitis

Vladimir Tesar, Prague, Czech Republic - New ways to interfere with the complement system

#### Giuseppe Remuzzi, Bergamo, Italy What precipitates IgAN and what is the target

for treatment? Genetic determination in IgA Nephropathy Krzysztof Kiryluk, New York, U.S.A.

- The intestine-renal connection Rosanna Coppo, Turin, Italy

Shall we treat intestinal immunity only? Bengt Fellström, Uppsala, Sweden

Shall we treat the systemic inflammation? Lessons from STOP IgAN Jürgen Floege, Aachen, Germany



Renal fibrosis: new insights

Perivascular progenitors, Hedgehog signaling and kidney fibrosis

Rafael Kramann, Aachen, Germany

The role of microvascular endothelium in progressive kidnev disease

Bernd Hohenstein, Dresden, Germany

New mediators of renal fibrosis, or the road to

Christos Chatziantoniou, Paris, France

Established mediators of renal fibrosis - where are the clinical trials?

Roel Goldschmeding, Utrecht, The Netherlands

Membranous nephropathy: new insights

The pathogenetic and clinical role of glomerular antigens in membranous nephropathy Rolf A.K. Stahl, Hamburg, Germany

The PLA2R autoantigen: from pathophysiology to patients' care

**Pierre Ronco**, Paris, France

Calcineurin inhibitors in membranous nephropathy Manuel Praga, Madrid, Spain

- Rituximab in membranous nephropathy Piero Ruggenenti, Bergamo, Italy

Immunology and the kidney

Österreichische Gesellschaft für Nephrologie

NETs, histories and necroinflammation in kidney

Hans-Joachim Anders, Munich, Germany

T cells in glomerulonephritis Kathrin Eller, Graz, Austria

Kidney dendritic cells in acute and chronic renal disease Christian Kurts, Bonn, Germany

- Intracellular signals as druggable targets in renal inflammation

Jesus Egido, Madrid, Spain

• The gut-renal axis

Österreichische Gesellschaft

- The gut microbiome in health and CKD Pieter Evenepoel, Leuven, Belgium

Targeting gut-derived uremic toxins Timothy Meyer, Palo Alto, U.S.A.

The nasal microbiome in granulomatosis with polyangiitis

Andreas Kronbichler, Innsbruck, Austria

IgAn and microbiota Loreto Gesualdo, Bari, Italy

CKD - Pathophysiology, epidemiology, prevention, progression, aging

• Lingering questions in CKD

- Is early nephrology care so important in stage 3b-4 CKD patients?

Goce Spasovski, Skopje, F.Y.R. of Macedonia

 Is sleep apnea a really major problem in CKD? Hypotheses and observations

**Sydney Tang**, Hong Kong, Hong Kong, P.R. China Pulmonary hypertension in CKD patients: Relevant? Preventable? Treatable?

Davide Bolignano, Reggio Calabria, Italy

- Directly acting anti-HCV agents: ready for use in CKD/ÉSRD? Michel Jadoul, Brussels, Belgium

Management of the frail and elderly with CKD

Nutritional status: evaluation and improvement **Denis Fouque**, Lyon, France

Should dialysis be different in the frail elderly? Olof Heimbürger, Stockholm, Sweden

Withholding and withdrawal of dialysis: models of care Jacques Bernheim, Tel Aviv, Israel

Models for prediction of need for RRT vs risk of death in the elderly

Evi Nagler, Ghent, Belgium

Aging and CKD

EVA & ADAM: impact on aging kidneys Alberto Ortiz, Madrid, Spain

- BOLD MRI: a key measure to diagnose ischemic nephropathy

Menno Pruijm, Lausanne, Switzerland

- Aortic aging in ESRD: structural, hemodynamic and mortality implications Gérard London, Paris, France

- New markers of frailty: myostatin Thomas Bernd Dschietzig, Bensheim, Germany

#### Gone with the Wnt

Wnt signaling in vascular calcification Mario Cozzolino, Milan, Italy

Wnt signaling in bone diseases Martine Cohen-Solal, Paris, France

Limitations of the current therapies for osteoporosis in patients with CKD

Susan M. Ott, Seattle, U.S.A.

Sclerostin and the CV System Vincent Brandenburg, Aachen, Germany

#### • New aspects of sex hormones abnormalities in **CKD** patients

- Testosterone deficiency - why it is important in male CKD patients

Mahmut Ilker Yilmaz, Ankara, Turkey

Hyperprolactinemia in CKD patients - friend or foe Juan Jesus Carrero, Stockholm, Sweden

Female infertility in CKD and antimüllerian hormone Marcin Adamczak, Katowice, Poland

Sexuality after successful kidney transplantation **Uwe Heemann**, Munich, Germany

Novel oral anticoagulants or warfarin in CKD?

 Is chronic anticoagulation treatment needed in chronic kidney disease?

Adrian Covic, Iasi, Romania

- Do novel oral anticoagulants differ from vitamin K antagonists for efficacy or bleeding? Jürgen Floege, Aachen, Germany

Stroke and bleeding in atrial fibrillation with chronic kidney disease

Anne Lise Kamper, Copenhagen, Denmark



Leading European Nephrology

- Novel oral anticoagulants or warfarin in CKD - a cardiologists perspective Karolina Szummer, Stockholm, Sweden

Lipids in nephrology

Lipoproteins in Nephrology: clinical importance and therapeutic options Kurt Derfler, Vienna, Austria

Lipid homeostasis in CKD: Focus on HDL cholesterol Marcus Säemann, Vienna, Austria

Lipid lowering in CKD: yes, no, maybe Christoph Wanner, Würzburg, Germany

Lipids and CKD progression: myth or reality? Alexander Rosenkranz, Graz, Austria

#### Bone, calcium and PTH in CKD

Österreichische Gesellschaft für Nephrologie

Österreichische Gesellschaft für Nephrologie

The rapidly exchangeable calcium pool in hemodialysis patients

Markus Pirklbauer, Innsbruck, Austria

Clinical evaluation of bone: what makes sense? Daniel Cejka, Vienna, Austria

What prophylaxis and therapy is really useful? Sylvie Dusilova Sulkova, Hradec Kralove, Czech Republic

**Uremic toxins and CKD-MBD** Ziad Massy, Paris, France

#### Track 5 End-stage renal disease, dialysis

#### Vascular access for HD

Pre-operative evaluation of vascular capital Pedro Ponce and Maria Guedes Marques, Portugal

- Predictors of fistula function Marko Malovrh, Radomlje, Slovenia

- Non-pharmaceutical and pharmaceutical strategies to enhance fistula maturation and primary patency Jan H. M. Tordoir, Maastricht, The Netherlands

Lock solutions to prevent clothing and infection in tunneled dialysis catheters Laura Labriola, Brussels, Belgium

#### **Nutrition in CKD patients**

Metabolic and clinical rationale for enteral support Denis Fouque, Lyon, France

Clinical trials update in CKD patients (including HD) Wilfred Druml, Vienna, Austria

Should enteral support be identical in HD and PD? Pieter M. Ter Wee, Amsterdam, The Netherlands

Low calorie diet in obese patients with CKD Fitsum Guebre-Egziabher, Grenoble, France

#### Calcification and calciphylaxis

Calcification in heart valves: clinical implications, consequences, therapy Pablo Antonio Ureña Torres, Saint-Ouen, France

- Vascular calcification in CKD patients: evaluation and outcomes

Teresa Adragao, Cascais, Portugal

New insights into the FGF23-Klotho axis Hannes Olauson, Cambridge, U.S.A.

- Uraemic calciphylaxis - clinical picture, course and therapeutic options Markus Ketteler, Coburg, Germany

#### Personalized dialysis

Frequent or longer hemodialysis - benefits more than risks?

Pantelis A. Sarafidis, Thessaloniki, Greece

Dialysis modality choice in diabetic patients with end-stage kidney disease

Davide Bolignano, Reggio Calabria, Italy

Dialysis modalities and interventions to reduce intradialytic symptoms

Andrew Davenport, London, United Kingdom

 Is online HDF the new standard for extracorporeal therapy? Francesco Locatelli, Lecco, Italy

#### Whole person care in Nephrology

Uremic pruritus and xerosis Jacek C. Szepietowski, Wrocław, Poland

The future impact of schistosomal nephropathies Rashad Barsoum, Cairo, Egypt

Fatigue in haemodialysis patients Maurizio Bossola, Rome, Italy

Psychological care of patients with CKD: Opportunities for relationship-centered care Marta Novak, Toronto, Canada

# Home therapies, peritoneal dialysis

#### • PD clinical science

EuroPD

 Bio-impedance: coming of age? Jeroen Kooman, Maastricht, The Netherlands

Transition between modalities: what do we (not yet) know?

Christopher T. Chan, Toronto, Canada

- Management of infections in PD Anabela Rodrigues, Porto, Portugal

Peritoneal dialysis catheter insertion and continuous access care: interdisciplinary challenges and preemptive practices

Catalin Buga, Bucharest, Romania

#### Should PD as initial dialysis modality become the standard of care?

CKDopps: Optimal timing of dialysis initiation and modality selection

Roberto Pecoits-Filho, Curitiba, Brazil Urgent Start of PD: PD First as standard of care? James Heaf, Copenhagen, Denmark

How can residual renal function be preserved? Sylvie Opatrná, Senec, Czech Republic

PDopps: Optimizing PD and reducing technique Simon Davies, Stoke-On-Trent, United Kingdom



Österreichische Gesellschaft

#### Quality Improvement in PD

- Updates on ISPD Peritoneal Dialysis Infection Guidelines Philip Li, Hong Kong, Hong Kong, P.R. China
- Integrating geriatric care for older patients on PD Edwina Brown, London, United Kingdom
- ISPD Cardiovascular and Metabolic Ğuidelines Rajnish Mehrotra, Seattle, U.S.A.

# **Track 7**Transplantation and immunology

# • Improving cardiovascular risk assessment in transplant patients

- Metabolic risk factor profile before and after renal transplantation

Adnan Sharif, Birmingham, United Kingdom

- Non-invasive cardiac imaging in the evaluation of kidney transplant candidates
- Alan G. Jardine, Glasgow, United Kingdom
   24h-ABPM in renal transplant patients: the nocturnal
  BP burden

Francesca Mallamaci, Reggio Calabria, Italy

- How to approach post-transplant diabetes? Marcus Säemann, Vienna, Austria

#### • The living kidney donor

- Development of CVD risk factors shortly after donation **Alaattin Yildiz**, Istanbul, Turkey
- The Oslo experience: long term risk after donation **Geir Mjøen**, Oslo, Norway
- Practice patterns for follow up of the kidney donors **Bruno Watschinger**, Vienna, Austria
- Psychological outcomes after living kidney donation **Hannah Maple**, London, United Kingdom

#### • Lingering issues in kidney transplantation

- Pre-emptive kidney re-transplantation If yes, when and for whom?
  Maria Alicja Debska-Slizien, Gdansk, Poland
- Immune surveillance after kidney transplantation Martina Sester, Homburg/Saar, Germany
- How to diminish the long-term renal allograft loss? Marian Klinger, Wroclaw, Poland

#### How to handle the sensitized kidney transplant recipient



- Precision diagnosis and risk stratification in kidney transplantation
  - Alexandre Loupy, Paris, France
- Desensitization protocols: is there a favorite? **Georg A. Böhmig**, Vienna, Austria
- Treatment of ABMR: when to treat and what tools do we have?
  - Søren Schwartz Sørensen, Copenhagen, Denmark
- Paired kidney donation
- Ondrej Viklicky, Prague, Czech Republic

#### DGF: how to prevent it?

- Intrarenal molecular events after death

Alberto Ortiz, Madrid, Spain

- Integrational aspects of DGF - towards a rational treatment

Rainer Oberbauer, Vienna, Austria

- Machine perfusion to preserve or to resuscitate: where are we today?

Ina Jochmans, Leuven, Belgium

- Ischemic pre-conditioning in kidney transplantation outcomes: is time for a trial?

Daniel Abramowicz, Antwerp, Belgium

#### Track 8 Hypertension, diabetes, vascular disease

#### • Salt on the table

- Salt consumption and cardiovascular disease: from etiology to prevention
   Francesco Paolo Cappuccio, Coventry, United Kingdom
- Salt consumption and renal outcomes **Johannes F.E. Mann**, Munich, Germany
- Dialysate sodium: friend or foe? **Mustafa Arici**, Ankara, Turkey

#### Uremic cardiomyopathy

- Thick but weak: the pathophysiology of uremic cardiomyopathy

Kerstin Ámann, Erlangen, Germany

- Non-invasive assessment of cardiac structure and function - what nephrologists must know Frank Flachskampf, Uppsala, Sweden
- Clinical consequences: cardiac arrhythmia and SCD Philip A. Kalra, Salford, United Kingdom
- Future perspectives in the treatment of uremic cardiomyopathy

  Marc Vervloet, Amsterdam, The Netherlands

#### Obesity and fat tissue - what is new and what is relevant for nephrologists?

- New classification of obesity not only BMI Bernhard Ludvik, Vienna, Austria
- Obesity a disease with many aetiologies disguised in the same oversized phenotype


Peter Stenvinkel, Stockholm, Sweden

 Metabolic syndrome and renal outcome a reappraisal

Andrzej J. Wiecek, Katowice, Poland

 Renal consequences of bariatric surgery the downsides
 Allon Friedman, Indianapolis, U.S.A.





Leading European Nephrology

#### Track 9 Acute kidney injury and intensive care nephrology

#### Cross-talk between kidneys and other organs in AKI

AKI and the heart

Claudio Ronco, Vicenza, Italy

AKI and the lung

Carmine Zoccali, Reggio Calabria, Italy

Novel evidence on the treatment of hepatorenal

Fabrizio Fabrizi, Milan, Italy

 AKI in pregnancy Fadi Fakhouri, Nantes, France

#### • AKI - pathophysiology and definition

Biomarkers as a tool to understand pathophysiology

Jill Vanmassenhove, Ghent, Belgium

Looking through RIFLE, AKIN and KDIGO glasses: do we see the same?

Marlies Ostermann, London, United Kingdom

Acute intestitial nephritis: an overlooked cause of AKI? Manuel Praga, Madrid, Spain

CKD imposed on AKI and vice versa Mehmet Sukru Sever, Istanbul, Turkey

#### Fluid management in the ICU

Prevent the kidneys from drowning - How to assess fluid status in ICÚ patients

Jan T. Kielstein, Braunschweig, Germany How to manage fluids in pediatric ICU patients?

Johan Vande Walle, Ghent, Belgium

- In whom when which type of fluid: state of the art Can Ince, Rotterdam, The Netherlands

- Fluid overload at cardiac ICU: diuretics, slow ultrafiltration or peritoneal dialysis? Jeroen Kooman, Maastricht, The Netherlands

#### Special technological aspects of ICU nephrology and extracorporeal treatment

- CO2 removal: indications, outcomes, technology Eric Hoste, Ghent, Belgium

Liver dialysis: technology, indications, outcomes Achim Joerres, Berlin, Germany

ICU dialysis in the paediatric setting: outcomes and technological considerations Franz Schaefer, Heidelberg, Germany

Extracorporeal treatment of immune mediated kidney disease

George Reusz, Budapest, Hungary

#### Special situations with need for nephrology advice

Prevention and management of AKI in the general ward: the UK experience

Nicholas Selby, Derby, United Kingdom

- How and when (not) to dialyse the frail and elderly with AKI

Wim Van Biesen, Ghent, Belgium

Pharmacokinetics of drugs in AKI and during RRT: what we should know? Jan T. Kielstein, Braunschweig, Germany

#### SPECIAL SYMPOSIA

Tomorrow's nephrology presented by the nephrologists of tomorrow

(YNP - Young Nephrologists' Platform)
- Update on YNP initiatives

Ana Carina Ferreira, Lisbon, Portugal Can we achieve personalized medicine in ADPKD? Emilie Cornec-Le Gall, Rochester, U.S.A.

Let's talk about death! Regulated necrosis in acute kidney injury

Andréas Linkermann, Kiel, Germany

Immune monitoring in kidney transplant recipients Oriol Bestard, Barcelona, Spain

Recent developments in atypical haemolytic uraemic syndrome **David Kavanagh**, Newcastle Upon Tyne, United Kingdom

ERA-EDTA Registry

ERA-EDTA Registry Leading European Nephrolog



Lifetime risk of Renal Replacement Therapy in Europe Jan Van Den Brand, Nijmegen, The Netherlands

 Transplanting kidneys from older deceased donors: a comparison of outcomes in young and old recipients Maria Pippias, Amsterdam, The Netherlands

Vascular access in children on hemodialysis Michael Boehm, Vienna, Austria

Prevalence of obese sarcopenia among elderly Stage 4 CKD patients and effect of muscle wasting on quality of life Marie Evans, Stockholm, Sweden

- Beta-blockers and outcomes in diabetic dialysis patients: data from EURODOPPS Christiane Drechsler, Würzburg, Germany

• Improving treatment of patients with CKD Joint Symposium ERA-EDTA & International

Society of Nephrology (ISN) Strategies to increase the donor pool and access to

transplantation

Rainer Oberbauer, Vienna, Austria

International guidelines: how relevant are they in developing countries? Faiçal Jarraya, Sfax, Tunisia

Transplantation in HIV populations: lessons learned Elmi Muller, Cape Town, South Africa

Variations in care and access to care Adeera Levin, Vancouver, Canada

• Joint symposium ERA-EDTA & ESC (European Society of Cardiology)

Cardiac function in CKD patients: how valuable are ECHO and biomarkers? Carmine Zoccali, Reggio Calabria, Italy

- Pathophysiology of hypertension in chronic kidney disease Speaker to be confirmed

- Uncontrolled hypertension - how to prevent unfavourable kidney outcome? Andrzej J. Wiecek, Katowice, Poland

- How low should blood pressure be lowered to protect the kidney in chronic kidney disease Josep Redon, Valencia, Spain





- Joint Symposium ERA-EDTA & European Society of Hypertension (ESH)
  - The kidney as a target of high blood pressure the evidence in 2016

Johannes F.E. Mann, Munich, Germany

- Renal angioplasty is there still an indication in hypertensive CKD patients with RAS? Patrick Rossignol, Vandoeuvre-Les-Nancy, France
- Which future for the treatment of hypertension with renal denervation?

Roland E. Schmieder, Erlangen, Germany

- Management of hypertension in patients with CKD Speaker to be confirmed
- Joint Symposium ERA-EDTA & European Society for Paediatric Nephrology (ESPN)
  - ADPKD: from Adult to Autosomal Dominant
  - Polycystic Kidney Disease?
  - Ron T. Gansevoort, Groningen, The Netherlands Management of cystic diseases from childhood to adulthood

- **Djalila Mekahli**, Leuven, Belgium KDIGO CKD-MBD Guideline Update 2016: Considerations in adults vs. children Markus Ketteler, Coburg, Germany
- HDF should this be the standard of care for
- Rukshana Shroff, London, United Kingdom
- Joint Symposium ERA-EDTA & Japanese Society of Nephrology (JSN)

  - The mechanisms of AKI to CKD continuum

Motoko Yanagita, Kyoto, Japan

Outcome of CKD-MBD: pathophysiology and management

Masafumi Fukagawa, Isehara, Japan Biomarkers of progressive renal disease - are we looking for the right ones? Gert Mayer, Innsbruck, Austria

Lipoproteins and outcome in CKD - the other view Danilo Fliser, Homburg/Saar, Germany

- **ASN Highlights** 
  - Glomerular Diseases Brad Rovin, Columbus, U.S.A.
  - Transplantation John Friedewald, Chicago, U.S.A. **ESRD**
  - Speaker to be confirmed
- The Dialysis Outcomes and Practice Patterns Study (DOPPS) Program:

Celebrating 20 Years and Looking Ahead
- The DOPPS Program continues to grow and invites

collaborators

Francesca Tentori, Ann Arbor, U.S.A.

- Key lessons from the first 20 years of DOPPS Michel Jadoul, Brussels, Belgium

Guideline adherence and drug prescription in EURODOPPS - Findings from the first proposal call **Sophie Liabeuf**, Amiens, France

- CKDopps: Improving outcomes in advanced CKD and the transition to dialysis Ziad Massy, Paris, France
- PDOPPS: the largest international study of PD practices Simon Davies, Štoke-On-Trent, United Kingdom
- Ethics in scientific research
  - Good scientific practice, sloppy science and research misconduct

Gerlinde Sponholz, Berlin, Germany

An ethical approach to the evidence-based development of clinical guidelines Evi Nagler, Ghent, Belgium

Scientific journals and conflict of interest disclosure Philippa Berman, London, United Kingdom

What is the impact of tightening animal rights on translational research: jumping from Petri dish to human?

Akos Koller, Budapest, Hungary

• NDT Polar Views - Should we correct vitamin D deficiency/insufficiency in CKD patients just treat them with active vitamin D forms? **ndt** with inactive forms of vitamin D or **PRO** 

David Goldsmith, London, United Kingdom CON

Rajiv Agarwal, Indianapolis, U.S.A.

- Late Breaking Clinical Trials
- The Lancet/The Lancet Diabetes THE LANCET and Endocrinology - Research
- The Lancet/The Lancet Diabetes THE LANCET and Endocrinology - Review
- Renal Replacement Therapy in Europe and in China

Joint Symposium ERA-EDTA & Chinese Society

of Nephrology (CSN)
- Transplantation data from Europe Rainer Oberbauer, Vienna, Austria

European perspective of Dialysis based on the ERA-EDTÁ Registry data Kitty Jager, Amsterdam, The Netherlands


CKĎ in China: current and perspective

Xueqing Yu, Guagnzhou, P.R. China Extracorporeal Therapies in Critical Care Nephrology: Experience from China

Yongchun Ge, Nanjing, P.R. China







Leading European Nephrology

#### **MASTERCLASS**

Managing PD patients -

**EUROPD** 

from basic principles to advanced practice

PD catheter: life line or strangling device? Martin Wilkie, Sheffield, United Kingdom

 Adequate PD prescription: balancing different interests

Simon Davies, Stoke-On-Trent, United Kingdom

#### **CME COURSES**

News in the diagnostics and treatment of glomerular disease (IWG - Immunonephrology Working Group)



Critical review of renal biopsy

- Indications for renal biopsy: when it is needed? Loreto Gesualdo, Bari, Italy

- Evidence based classification of renal pathology Ian Roberts, Oxford, United Kingdom

Can biomarkers substitute renal biopsy in IgA nephropathy?

Yasar Caliskan, Istanbul, Turkey

What is the added value of renal biopsy and rebiopsy to clinical data in lupus Gabriella Moroni, Pavia, Italy

What is the added value of renal biopsy to clinical data in vasculitis **Ingeborg M. Bajema**, Leiden, The Netherlands

4 years after the KDIGO guidelines on glomerular diseases: when to update them?

- Membranous nephropathy

Jack F.M. Wetzels, Nijmegen, The Netherlands

IgA nephropathy

Jürgen Floege, Aachen, Germany FSGS/minimal change disease

Rosanna Coppo, Turin, Italy

- Lupus nephritis

David Jayne, Cambridge, United Kingdom

ANCA-associated vasculitis

Vladimir Tesar, Prague, Czech Republic

Practical issues in kidney transplantation (DESCARTES Working Group -

Developing Education Science and Care for Renal Transplantation in European States) In collaboration with EKITÂ,

a section of ESOT

- Indications and complications of bariatric surgery before and after transplantation Franco Citterio, Rome, Italy

Transplantation into an abnormal lower urinary tract: what should the nephrologist know? Licia Peruzzi, Turin, Italy

Thrombotic microangiopathy in kidney allograft how to proceed? Christophe Legendre, Paris, France

- Risk scores in kidney transplantation: how useful are they?

Marc Hazzan, Lille, France

How to avoid DGF: patient perfusion or machine kidney perfusion?

Rainer Oberbauer, Vienna, Austria

How can you improve the outcomes of your kidney transplant program?

Daniel Abramowicz, Antwerp, Belgium Assessment of recipient alloreactivity before

transplantation

Ondrej Viklicky, Prague, Czech Republic

Should we treat asymptomatic bacteriuria after renal transplantation?

Julien Coussement, Brussels, Belgium

 A preview of the future in cardiovascular risk management in CKD EURECA-m (EURECA-m Working Group -**EUropean REnal and CArdiovascular Medicine**)

Uremic toxins, genetics and systemic disorders at the kidneycardiovascular system interface

- Future pathways to decrease concentration of cardiotoxic urémic toxins Raymond Vanholder, Ghent, Belgium

 Genetic epidemiology of the cardio-renal risk linked to urate transporters

Francesca Mallamaci, Reggio Calabria, Italy

Hypertension in systemic diseases Andrzej J. Wiecek, Katowice, Poland

Decreasing adverse cardiac outcomes in CKD

 Renal congestion in heart failure: concept and impact on outcome

Mehmet Kanbay, Istanbul, Turkey

- Novel therapeutic approaches to heart failure in CKD

Patrick Rossignol, Vandoeuvre-Les-Nancy, France

- How to prevent sudden death in chronic kidney disease Gunnar Heine, Homburg/Saar, Germany

Hemodiafiltration - the new standard of care? (EUDIAL Working Group -(MEUDIAL) **European Dialysis Working Group)** 

How to dose dialysis therapy: paradigm shift from urea to volume

Why should higher volume on-line haemodiafiltration improve survival? Carlo Basile, Taranto, Italy

- Hydration status and survival in haemodialysis patients

Andrew Davenport, London, United Kingdom

- Does achieving bioimpedance guided normovolaemia increase intradialytic hypotension and loss of residual renal function? Frank M. Van Der Sande, Maastricht, The Netherlands



Recent trials in HDF

Clinical evidence on HDF

**Peter J. Blankestijn**, Utrecht, The Netherlands Incremental dialysis - does less dialysis preserve residual renal function?

Enric Vilar, Stevenage, United Kingdom HDF around the globe: acceptance and regulatory issues worldwide

Bernard Canaud, Montpellier, France

- Achieving more frequent and longer dialysis: compelling evidence from clinical trials? Speaker to be confirmed
- Diabetes and obesity in renal disease (DIABESITY - Working Group researching on the nephrological impact in relation to diabetes and obesity)

The effect of weight loss in obesity and chronic kidnev disease

Enrique Morales, Madrid, Spain

Renal lipotoxicity: evidence of lipid deposits in human kidneys

Esteban Porrini, La Laguna, Spain

Glycemic control in patients with kidney disease: how to individualize the treatment Drazenka Pongrac Barlovic, Ljubljana, Slovenia

NAFLD and microalbuminuria in the Netherlands **Epidemiology of Obesity Study** 

**Aiko De Vries**, Leiden, The Netherlands

- Macrophages and diabetic kidney disease Josep Cruzado, Barcelona, Spain

The role of glomerular hyperfiltration in renal disease in obesity and diabetes Avry Chagnac, Petah Tikva, Israel

EUROPEAN RENAL NUTRITION As we grow old - nutritional considerations for the CKD elderly patient (ERN - European Renal Nutrition Working Group)

The growing population of elderly dialysis patients: prevalence and consequences of protein-energy wasting

**Siren Sezer**, Ankara, Turkey

Diagnosing protein-energy wasting in the elderly dialysis patient: Should it be any different from younger patients?

**Ĺina Johansson**, London, United Kingdom

Nutritional requirements and nutritional management of elderly dialysis patients: should it be any different from younger patients? **Daniel Teta**, Sion, Switzerland

Sarcopenia and frailty in the elderly dialysis patient: concepts of clinical applicability or just theoretical artifacts?

Juan Jesus Carrero, Stockholm, Sweden

Physical activity in the elderly dialysis patient Anne Kolko-Labadens, Saint-Ouen, France

Treating the whole patient: Emphasizing quality of life **Vincenzo Bellizzi**, Salerno, Italy

- Dialysis technique choice for the elderly dialysis patient: impact on nutritional status Pieter M. Ter Wee, Amsterdam, The Netherlands  Inherited Disorders: the kidney and beyond (WGIKD - Working Group ( WGIKD) on Inherited Kidney Disorders)

 Mitochondrial disorders Francesco Emma, Rome, Italy

Intellectual disability and kidney disease Nine V.A.M. Knoers, Utrecht, The Netherlands

Guidance and consensus reports on Fabry disease Roser Torra, Barcelona, Spain

When the kidney biopsy speaks Renate Kain, Vienna, Austria

News from the Impulsions Grants: Role of endolysosomes and autophagy in Dent disease Alessándro Luciani, Zurich, Šwitzerland

News from the Impulsion Grants: Identification and functional characterization of new magnesiotropic

Francisco J. Arjona Madueno, Nijmegen, The Netherlands

News from the WGIKD Olivier Devuyst, Zurich, Switzerland

 New insights into CKD-MBD (CKD-MBD Working Group)

@CKD-MBD €

Will Klotho and FĞF23 make you change your clinical practice?

Marc Vervloet, Amsterdam, The Netherlands

Alkaline phosphatase Jordi Bover, Barcelona, Spain

Phosphate

DIABESITY

Mario Cozzolino, Milan, Italy

What do observational and intervention studies teach us? David Goldsmith, London, United Kingdom

PTH resistance in CKD

Pieter Evenepoel, Leuven, Belgium

What is the role of bone biopsy and bone biomarkers?

Pablo Antonio Ureña Torres, Saint-Ouen, France

 Peritoneal dialysis in 2016 where do we stand? (EuroPD)



Peritoneal membrane physiology and anatomy in 2016 Bert Bammens, Leuven, Belgium

Writing a suitable PD prescription in 2016 Monika Lichodziejewska-Niemierko, Gdańsk, Poland

Understanding infection in PD Andreas Vychytil, Vienna, Austria

Nutrition in PD patients: still a cause of concern in 2016?

Juan Jesus Carrero, Stockholm, Sweden


Survival on PD - trends until 2016? Moniek Van De Luijtgaarden, Amsterdam, The Netherlands

Keeping the patient euvolemic

Simon Davies, Stoke-On-Trent, United Kingdom

Home HD: Do's and dont's and underlying rationale Wim Van Biesen, Ghent, Belgium





Leading European Nephrology

Uraemia: is it only a toxin affair? The emerging concept of networking (EUTox Working Group - European Uremic Toxin)

Uraemia: is it only a toxin affair? The emerging concept of networking

Uraemia and endothelial cells Stéphane Burtey, Marseille, France

The renal tubular handling of uremic metabolites Rosalinde Masereeuw, Utrecht, The Netherlands

Uraemia and blood cells Griet Glorieux, Ghent, Belgium

CKD modification of the agonists and receptors: the integrative view of uraemic toxicity

Post translational modifications of the agonists in CKD Vera Jankowski, Aachen, Germany

Receptors and altered target organs response in CKD J. Mariano Rodriguez, Cordoba, Spain

The emergence of networking concept in uraemic toxicity: the integrative view Alberto Ortiz, Madrid, Spain

Rheumatology for nephrologists

Management of RA patients with CKD Volker Vielhauer, Munich, Germany

Gout management in CKD Hans-Joachim Anders, Munich, Germany

Kidney manifestations in Primary Sjögrens Syndrome Dana Kidder, Aberdeen, United Kingdom

Scleroderma - an update for nephrologists **Ariane Herrick**, Manchester, United Kingdom

- My lupus nephritis patient has persistent proteinuria - what to do?

David Jayne, Cambridge, United Kingdom

The topoisomerase I inhibitor irinotecan as a new treatment option for lupus nephritis? Steffen Frese, Berlin, Germany

Disasters and the Nephrologist

The conceptual evolution of renal disasters Garabed Éknoyan, Houston, U.S.A.

Renal Disaster Relief Task Force - Why was it founded? What did it achieve? Norbert H. Lameire, Ghent, Belgium

Kidney problems in disasters other than earthquakes Raymond Vanholder, Ghent, Belgium

Lessons learned from past disasters Mehmet Sukru Sever, Istanbul, Turkey

• Amyloidosis - old problem, new issues

Amyloidosis - not so rare but underappreciated problem in nephrology Jolanta Malyszko, Bialystok, Poland

 New types of amyloidosis in their clinical relevance Romana Rysava, Prague, Czech Republic

- Diagnosis of amyloidosis - the easy and the not so easy diagnosis

Sanjeev Sethi, Rochester, U.S.A.

Promising new treatments of amyloidosis Helen Lachmann, London, United Kingdom Including the patient perspective in renal care

Understanding quality of life in older people with

Casper Franssen, Groningen, The Netherlands

- Insights into the illness perceptions of older people with late CKD

Friedo W. Dekker, Leiden, The Netherlands

Using patient-reported outcomes in the clinic: lessons from other specialties

Sabine Van Der Veer, Manchester, United Kingdom

Routine collection of data on the patient perspective in renal registries: a European perspective Fergus Caskey, Bristol, United Kingdom

Transplantation immunology - an update
 Update on donor cell specific antibodies

Christophe Legendre, Paris, France
- Recurrent and de novo glomerulonephritis after transplantation

Claudio Ponticelli, Milan, Italy

Transplant glomerulopathy Miklos Zsolt Molnar, Memphis, U.S.A.

Progress in transplantation tolerance Ondrej Viklicky, Prague, Czech Republic

- Novel immunosuppressives Josep M. Grinyó, Barcelona, Spain

• Prescription for health -Exercise as part of nephrological care

(In collaboration with EURORECKD - European Association of Rehabilitation in Chronic Kidney Disease)

Learning from the EXCITE study Carmine Zoccali, Reggio Calabria, Italy

Exercise as medicine in CKD - experiences over 30 years Naomi Clyne, Lund, Sweden

Exercise with dialysis patients - benefits for cardiovascular health

Evangelia Kouidi, Thessaloniki, Greece

Benefits and challenges of exercise rehabilitation for kidney transplant recipients Tom Mercer, Edinburgh, United Kingdom

Exercise prescription for health: Recommendation with reference to chronic kidney disease Herbert Löllgen, Remscheid, Germany

 Non-pharmacological treatment of resistant hypertension - consensus for 2016

Selecting patients for renal denervation **Peter J. Blankestijn**, Utrecht, The Netherlands

Baroreceptor activation: still an option? Jan Menne, Hannover, Germany

Renal revascularization in high risk patients with RAS Philip A. Kalra, Salford, United Kingdom

Central arteriovenous anastomosis Roland E. Schmieder, Erlangen, Germany


 Less is more: why 'treating to targets' does not improve outcome of CKD patients?

 Rise and fall of Hb target in CKD: from 'high normal' to 'just avoid transfusion'? Francesco Locatelli, Lecco, Italy




- Treatment of cardiovascular disease in CKD: does it really help?
  - Tomasz Stompor, Olsztyn, Poland
- Treatment of CKD-MBD and outcome: any good news since KDIGO 2009?
- Markus Ketteler, Coburg, Germany
- Controversies in dialysis: when to start Jonathan G. Fox, Glasgow, United Kingdom
- Nephrolithiasis and CKD
  - (In collaboration with EULIS,
  - the EAU Section of Urolithiasis) - Risk of CKD in stone patients: the epidemiology perspective
    - Pietro Manuel Ferraro, Rome, Italy
  - The renal damage by urological treatments
  - Alberto Trinchieri, Lecco, Italy Struvite stones: difficult to treat, difficult to prevent Giovanni Gambaro, Rome, Italy and Christian Türk, Vienna, Austria
  - Nephrolithiasis and PKD (with an embedded clinical case) Dominique Chauveau, Toulouse, France
- Crosstalk in renal epidemiology ERA-EDTA Registry (Replacement) (ERA-EDTA Registry)
  - Translational research in nephrology Public Health Simon Fraser, Southampton, United Kingdom


- Chances and challenges of using routine data collections for renal health care research Gert Mayer, Innsbruck, Austria
- The credibility of subgroup analyses Georg Heinze, Vienna, Austria
- Choosing the correct competing risk method not always straightforward Vianda Stel, Amsterdam, The Netherlands
- STROBE and the quality of reporting observational studies in nephrology
  - Fergus Caskey, Bristol, United Kingdom
- Toxicology for nephrologists
  - Overview of elimination enhancement techniques in poisoning
    - Speaker to be confirmed
  - Summary of the available extracorporeal treatments in poisoning
    - Jan T. Kielstein, Braunschweig, Germany
  - EXTRIP guidelines for extracorporeal removal of toxins: methodology and recommendations Marc Ghannoum, Montreal, Canada
  - Presentation of the EXTRIP process to a new toxin (Dabigatran)
    - Robert Mactier, Glasgow, United Kingdom







Leading European Nephrology



53rd CONGRESS VENNA MAY 21"-24", 2016 AUSTRIA

#### **Congress Information**



#### **ADMISSION**

Admission to the scientific sessions is strictly reserved to registered congress members. Minors cannot access the session halls even if accompanied by a registered adult. ERA-EDTA as per EFPIA HCP Code does not extend hospitality in any way to persons other than the registered delegates.

#### **CERTIFICATE OF ATTENDANCE**

The certificate of attendance will be sent to all regularly registered delegates by email after the congress. In case you do not receive it, please write to registrations@era-edta.org. If you need a hard copy, you can collect it at the dedicated desk located in the Registration Area of the **Austria Center Vienna**.

Please notice that the certificate will specify the exact number of days that you will have attended the congress.

#### **CME COURSES**

Participation in the CME Courses on May 21, 2016 will be on a "first come first served" basis. The courses are reserved to regularly registered congress members and are included in the registration fee.

In order to participate all regularly registered congress members must go to the session halls and have their badge scanned by the hostesses at the entrance (at participant's own responsibility).

#### **INSURANCE/LIABILITY**

The ERA-EDTA is insured only to meet claims arising from incidents caused by the organisers and their equipment. Participants, exhibitors and visitors are strongly recommended to be properly insured against accidents they may suffer when travelling to and from the Congress and during the Congress itself.

#### LANGUAGE OF THE CONGRESS

The official language of the Congress is English. No simultaneous translation will be provided.

#### PRESS CENTRE

For accredited journalists only. Full press working facilities and activities including press conferences, press releases and services for press will be available at the Austria Center Vienna during the Congress

#### **UEMS CME CREDITS**

An application will be made to the European Accreditation Council for Continuing Medical Education (EACCME) for CME accreditation of the 53<sup>rd</sup> ERA-EDTA Congress and pre-congress CMEs. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Delegates receiving certificates for ECMEC credits must contact

their National Accreditation Authority to have the credits recognized (or converted) in their country of practice. EACCME credits are recognized by the American Medical Association (AMA) towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, you should contact the AMA directly. The total number of CME credits given to the ERA-EDTA Vienna Congress will be posted on the website (www.era-edta2016.org) as soon as they are available.

#### How to receive UEMS CME credits

ERA-EDTA will track attendance of congress members during the congress in the Austria Center Vienna each day. Regularly registered congress members must go to the session halls and have their badge scanned by the hostesses at the entrance (at participant's own responsibility). Congress members will then be awarded the number of credits towards the hours actually spent participating in the sessions of the congress.

ERA-EDTA will send UEMS CME certificates to all regularly registered participants by email approximately one month after the end of the Congress. In case you do not receive it by that time, please write to cmecredits@era-edta.org.


#### **VENUE**

Austria Center Vienna IAKW - AG Internationales Amtssitz- und Konferenzzentrum Wien, AG Bruno-Kreisky-Platz 1 A-1220 Vienna Austria

www.acv.at/index.en.html







# Congress Membership Fees and Deadlines

#### **CONGRESS MEMBERSHIP FEES AND DEADLINES**

STATUS	LATE	ONSITE	
	From February 25 to April 27, 2016	From April 28 to May 24, 2016	
ERA-EDTA / ÖGN MEMBER # (individual and regular group)	EUR 380.00	EUR 400.00	
ERA-EDTA NON MEMBER (individual and regular group)	EUR 550.00	EUR 600.00	
STUDENT/TRAINEE*		EUR 280.00	
LOCAL STUDENT**		EUR 60.00	
1-2 DAYS ERA-EDTA / ÖGN MEMBER ***		EUR 140.00 (1 day) EUR 270.00 (2 days)	
1-2 DAYS NON MEMBER		EUR 180.00 (1 day) EUR 350.00 (2 days)	

# IMPORTANT: Please note that congress members submitting and paying their congress membership fee as non-members will not be entitled to reimbursement if, at a later stage, they become members.

Once the congress membership has been processed it cannot be changed or reimbursed.

- \* Student/trainee congress memberships are available online starting from April 28, 2016. You can also register onsite at the Austria Center Vienna starting from May 20, 2016. In order to be eligible for this fee, students/trainees must be 35 years old or younger, thus the birth year must not be earlier than 1981 furthermore the congress membership cannot be sponsored by a company/agency/institution etc. You must personally hand over a photocopy of your picture ID (passport, identity card, driving license with birth date), a photocopy of your original student's card and a signed letter from your mentor/university to prove your student/trainee status. ERA-EDTA reserves the right to verify all declarations.
- \*\* Local student congress memberships are available online starting from April 28, 2016. You can also register onsite at the Austria Center Vienna starting from May 20, 2016. This exceptionally low congress membership fee is reserved for students living in the country where the congress is held (Austria). In order to be eligible for this fee, local students must be 28 years old or younger, thus the birth year must not be earlier than 1988 furthermore the congress memberships cannot be sponsored by a company/agency/institution etc. In order to register with this special fee you must personally hand over a photocopy of your picture ID (passport, identity card, driving license with birth date), a photocopy of your original student's card and a signed original letter from your mentor/university to prove your student status. ERA-EDTA reserves the right to verify all declarations.
- \*\*\* 1- 2 Days congress memberships are available online starting from April 28, 2016. You can also register onsite at the Austria Center Vienna starting from May 20, 2016. This type of congress membership entitles admission to the session and poster and exhibition halls only on the date mentioned on the congress badge as well as to receive the bag, the proper

EACCME/UEMS Credits and Certificate of Attendance for that same day. It is also possible to make two one-day congress memberships if you are able to attend the congress for two days (consecutive or not).

#### **HOW TO REGISTER**

All congress memberships must be submitted online at www.era-edta2016.org.

#### METHOD OF PAYMENT

You can pay online by credit card (Visa, MasterCard and American Express) at the same time as you submit your congress membership or by direct money transfer to the ERA-EDTA bank account.

Cash payments (EUR) are accepted only onsite.

#### **CANCELLATION POLICY**

Before April 28, 2016	After April 28, 2016
75% of the amount paid,	No refund
net of bank charges.	of the amount paid.

No name changes are possible

#### **ERA-EDTA MEMBERSHIP INFORMATION**

New applicants and members with outstanding membership fees, wishing to sign up/pay for ERA-EDTA membership in order to benefit from the reduced congress membership registration fee, must apply for membership, or pay the outstanding fees, no later than 10 working days prior to the respective registration deadlines. Please note that congress members submitting and paying their registration fee as non-members will not be entitled to reimbursement if, at a later stage, they become members.

Please check the website www.era-edta2016.org

for full information on the congress membership rules



### BOOKING YOUR OWN CONFERENCE TRAVEL IS EASY AS ABC

WITH THE GLOBAL ONLINE BOOKING TOOL FROM STAR ALLIANCE CONVENTIONS PLUS

No matter where you are travelling from, the Star Alliance™ network offers you a wide choice of flights to the 53rd ERA-EDTA Congress in Vienna, Austria.

And with over 18,500 flights a day to 1,330 destinations across 192 countries, our 28 member airlines extend the same choice to any future conferences you are planning to attend.

You can also save money when you book your flights. Simply quote the Convention Code OS14S16 and you plus one travelling companion will receive a special discount. Better still, no matter which Star Alliance member airline's frequent flyer programme you belong to, you can earn and redeem miles across all 28 airlines.

For more information, or to join the airline network that offers you more choice wherever your conferences take you, simply go to www.staralliance.com/conventionsplus



UNITED

ADRIA





Leading European Nephrology



The Austrian capital is world-famous for its rich cultural and historical heritage, that can be sampled in the 100 musums or just by strolling the streets of the old city centre, that belongs to the UNESCO world cultural heritage. Vienna is known as one of the music capitals of the world. There is no other city where so many famous composers have lived, and music tradition is kept alive in Vienna's famous opera house and concert halls. Modern musicals have replaced the old operetta, with two theatres devoted to this genre alone. Nowadays Vienna is also known as a modern art centre and a city with a very high quality of life. In addition to sites of historical interest the city offers fine examples of innovative architecture, fashionable shopping areas, and moreover samples of Viennese lifestyle in its traditional coffee houses, the Heurigen (wine taverns), trendy bars, sausage vendors and clubs.

Headquarter City

Vienna is one of the 4 official seats of the United Nations and home to 15 UN organizations, OSZE and OPEC as well as 18 other international organizations.

200 international corporations have their Eastern European headquarters in Vienna (incl. JVC, Heineken, Henkel, Beiersdorf, Siemens) in addition to Austrian companies of global significance (e.g. Wienerberger AG, OMV). Every year, over 100 international companies open a branch office in Vienna.

**Knowledge City** 

Over 34,000 people work in Vienna in the field of research and development, 43% of all research activities in Austria take place in Vienna.

# About Vienna

The city has 9 public universities, 5 advanced technical colleges and 6 private universities, with a population of over 160,000 students, the largest university city in the German-speaking region.

Congress City

In 2014 there were 1458 associations' congresses in Vienna, and 2124 corporate events were held in the city in the same year.

In 2015 Vienna holds the second place worldwide in the ranking list of the most sought-after destinations for international congresses (ranking list provided by the ICCA: International Congress and Convention Association).

#### **Diverse City**

Formerly the capital of a multicultural and multilingual empire, Vienna has retained its international flair. 570,000 people of international origins from 198 countries live in Vienna, 200,000 from EU Member States. 49% of Viennese have a migrant background (either personally born outside of Austria or with at least one parent born elsewhere).

#### Travel to Vienna

Thanks to its central location in the heart of Europe, the city of Vienna is easy to get to by air, by train and by car. The maximum direct flight time from any European capital is less than three hours.

By air

Vienna International Airport is located Vienna-Schwechat, 19 km south east of the centre.

The airport offers an extensive route network and perfect infrastructure as well as high comfort and excellent orientation systems.



#### AIRPORT TRANSFERS City Airport Train (CAT)

Non-stop from airport to city centre in just 16 minutes without any stops, every 30 minutes from 05:38 till 23:08, airport check-in at Wien-Mitte City Air Terminal. Single ticket EUR 11,00, return ticket EUR 17,00. Tickets bookable online at www.cityairporttrain.com.

#### Airport bus

To Schwedenplatz/Morzinplatz: departures every 30 minutes from 04.50 till 00.20, journey time 22 minutes. To West Railway Station/Europaplatz: departures every 30 minutes from 06:00 to midnight, journey time 45 minutes. To Donauzentrum: departures every hour from 07:10 to 20:10, journey time 40 minutes.

Single ticket EUR 8,00, return ticket EUR 13,00.

For information: www.postbus.at.

#### Railroad (S-Bahn line S7)

It runs underneath the airport and takes passengers to the city centre (subway and train connections). Trains leave about every 30 minutes from 04:54 to 00:18, journey time 25 minutes. Price: EUR 4,00.

#### **Taxis**

Journey time is approximately 20 minutes to inner city. Price for one way is approximately EUR 36,00.

#### By train

Austrian Federal Railways (ÖBB) offer a well-developed railway network and modern trains that carry you to Vienna in safety and comfort. Vienna can also be easily reached by train from further afield.

The ÖBB offer discounts for various groups.

#### By car and bus


Austria has an excellent network of motorways, expressways and federal highways. From across Europe, Vienna can be reached by the bus company Eurolines and by national companies.

#### Travel in Vienna

Public Transport is safe, clean, fast, efficient and reasonably priced. It consists of a wide network of 5 subway lines (U-Bahn), 28 streetcar lines (trams), 100 bus lines, 31 night lines with short intervals (at peak times 3 to 5 minutes, in the evenings 5 to max. 15 minutes) and operating hours 05.00 to 00.30, night lines from 00.30 to 05.00, night subways every 15 minutes during nights before Saturdays, Sundays and public holidays.

Tickets are available:

- from 27 Wiener Linien ticket offices,
- from about 1,100 tobacconists,
- from over 340 ticket machines,
- on every streetcar and every bus.



Special tickets are available with Wiener Linien at <a href="https://shop.wienerlinien.at/index.php/special\_customer/710/join/rbhuci9nEs">https://shop.wienerlinien.at/index.php/special\_customer/710/join/rbhuci9nEs</a>

1-day-ticket: EUR 6,842-day-ticket: EUR 10,80

3-day-ticket: EUR 14,764-day-ticket: EUR 16,74

# MIENER LINIEN

#### **Currency**

The currency in Austria is the Euro ( $\notin$  / EUR). Credit cards are widely accepted.

#### Climate

Weather in Vienna is typically continental, with characteristic, clearly defined seasons. Hot summers with an occasional day of rain and the cold winters mean that the "right" clothing is essential. The temperature is pleasant in the spring and autumn, but there can be cool winds to chill the air. Average temperature in May is 15-20° C.

#### Language

The mother tongue of Austria is German, and the most commonly spoken foreign language is English.

#### Electricity

Austria uses 220 Volts AC/alternating current. Plugs and sockets are European standard with 2 round pins.

#### Shopping

Most shops are open Monday through Friday from 9.00 till 18.30 hrs and Saturday till 17.00 or 18.00 hrs.

There are three main shopping areas in Vienna: the Old Town – Vienna's own special note, the Kohlmarkt & Kärnterstrasse - cool elegance and stylish glamour in exclusive boutiques and the Mariahilferstrasse - the city's longest and most lively shopping street.

#### Time Zone

Vienna is in the Central European time zone (CET = GMT / UCT + 1). From the last Sunday in March to the last Sunday in October, summer time is in effect (MESZ).

#### **Tourist Information**

For info on sightseeing, tips for dining, shopping, cultural events please visit the official Vienna tourist guide

www.vienna.info/en.





#### **Passport and Visa Information**

Leading European Nephrology

#### VISA/INVITATION LETTER

An invitation letter for visa purposes can be obtained through the ERA-EDTA 53rd Congress website www.era-edta.2016. Should this not be sufficient, the Visa Secretariat will be pleased to send, upon request, a personal invitation to all participants. This letter should NOT be considered as an offer of any kind of financial support on behalf of the organizers. An official invitation letter can be requested by email to the President of the Congress Prof. Gert Mayer (visa@era-edta.org) at least three months in advance. This letter however does NOT involve any commitments by the Congress Organizers to cover fees, accommodation, travel expenses or other costs connected to the participation in the Congress. ERA-EDTA will not be held responsible for visas that are not granted. International registrants who require a letter of invitation, will first need to complete the online registration for the 53rd ERA-EDTA Congress. Letters of invitation for spouse/guest registrants will only be provided if the accompanying individual has completed his or her congress registration.

#### Those who do not require a visa

Nationals of EU member states, the European Economic Area (EEA) and Switzerland do not require a visa for entering the Republic of Austria.

EU nationals may travel with a passport or national ID card which is valid for the duration of stay.

If travelling from one border-free Schengen country to another, however, EU nationals are not required to show a passport or national ID card at the border. It is mandatory to travel with your passport or ID card to prove your identity when boarding a flight or checking-in at hotels.

A passport valid for three months beyond the length of stay and issued within the past 10 years is required by all nationals of Australia, Canada, UK and USA. Nationals of Australia, Canada, UK and the USA may stay for up to 90 days without a visa. A return ticket might be required for nationals of Australia, Canada and USA.

For information on nationals of visa-free countries please check www.bmeia.gv.at/en/travel-stay/entry-and-residence-in-austria/entry-and-visa/schengen-visa.

All other nationals require a visa in order to enter the Schengen Area or the Austrian territory. For stays of up to 90 days per 180 days these individuals require a Schengen visa, given that they do not take up employment.

#### Those who need a visa

#### SCHENGEN VISA

The uniform Schengen visa is a short stay visa (e.g. tourism, private visits, short business, conference) for all Schengen countries (Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland).

Third country nationals who want to travel to the Schengen countries can apply for short stay visas (up to 90 days), which is valid for all Schengen countries. Once you have obtained a visa for one Schengen country, it automatically permits you to enter and travel through any other Schengen country too. Further information on visa regulations and Schengen visas

can be found at www.bmeia.gv.at/en. The application itself does not automatically give the right to travel or to get a visa. Visas can only be issued if all necessary preconditions are met. Visa applications have to be lodged at the Austrian Embassy or Consulate in your country of residence. For a list of Austrian representations please check www.bmeia.gv.at/en/embassiesconsulates.

According to each individual case the competent embassy or consulate can ask for further documentation. Please verify with the website of the respective diplomatic representation.

#### APPLICATIONS for short term visas

(tourism, private, business, conference)

All visa applicants must apply at the Austrian Embassy or Consulate in person.

#### Necessary requirements/documents:

- Completed and signed application form.
- Passport picture meeting the ICAO (International Civil Aviation Organisation) criteria (color, 35x45mm).
- Passport (must provide at least two empty pages; the first issue date of your passport must not be more than 10 years ago and the passport must be valid for at least three months after the expiry of the applied visa).
- In some representations applicants must submit biometric data (ten fingerprints taken flat and digitally scanned).
- Copy of passport's data sheet (containing the passport picture).
- Copies of previous Schengen visa, if any.
- Travel itinerary/reservation (it is not required to submit a prepaid ticket!).
- Travels by car: driver's licence, green insurance card, certificate of approval.
- Travel, health and accident insurance (limit of liability at least EUR 30.000 and return journey) valid for the Schengen Area.
- For students: confirmation of enrolment (Studienbestätigung).
- Notarised letter of authority of parents of underage children, who travel unaccompanied by their parents.

#### In addition further documents are required:

- Hotel reservation.
- Proof of sufficient financial means.
- Original invitation to the conference (from conference/ congress organisers).
- Proof of registration (payment of registration fee, if applicable).

#### Consular fees

A decision on a visa application is only possible after the payment of the consular fee and the submission of all documents requested by the consulate. The fee for a visa application for a period of validity of up to 90 days is in general EUR 60,00.

#### **IMPORTANT NOTES**

Applications cannot be submitted more than 3 months prior to departure. However please **present your application at least 2 months** before the intended travel.

The consular fees have to be paid when lodging the application; they are not reimbursed in case of refusal.

All points of the visa application form have to be filled in completely and correct. Documents missing may cause inadmissibility of the application or delay the application.

#### **Hotel Accommodation**



C-IN has been appointed as the official housing agent for the upcoming 53rd ERA-EDTA Congress 2016 in Vienna. Room blocks at special rates are being held in most of Vienna hotels of various categories. Hotels are mostly located in the city centre with good connection (U-Bahn) to the venue (Austria Center Vienna).

#### C-IN

(CZECH-IN s.r.o.)

5. kvetna 65

140 21 Prague 4, Czech Republic Tel: + 420 261 174 304 (or 301)

Fax: + 420 261 174 307

Email: hotels.eraedta2016@c-in.eu


web: www.c-in.eu

A full hotel list, inclusive of rates, hotel maps and all relevant info is available on www.era-edta2016-booking.cz. Please note that availability in some of the hotels may be limited. Room rates are indicated per room/per night incl. breakfast and VAT (VAT may be subject to change). Room blocks are being sold on a first-come-first-served basis and an early reservation is highly recommended.

#### **Group Reservations**

Please kindly send your request to C-IN at the following address: hotels.eraedta2016@c-in.eu and please do not forget to include all essential information: number of rooms required, arrival and departure dates, room





type, preferred hotel or area. An offer based on your requirements will be provided at soon as possible. Alternatively, please feel free to contact us anytime at the above telephone numbers.


#### **Individual Reservations**

Individual hotel bookings can be done online via a link on the official Congress website. After completing the hotel booking, the applicant will receive a system notification that reservation request was received (this is not a confirmation of the room). Confirmation of the hotel booking will be issued only after the prepayment is received. Full prepayment is required to guarantee the room. Changes and cancellations must be made in writing to C-IN; the hotels will not accept direct changes. A handling fee of EUR 30,00 will be charged for any change of reservation. Refundable cancellations can be made until March 11, 2016 and the prepaid amount will be refunded, minus a handling fee of EUR 60,00. If your room is cancelled after March 11, 2016, or if you arrive later or depart earlier than reserved, the total amount of accommodation will be charged and no refund can be made.



Leading	European	Nephrolo	g١

Rating	Hotel name	Area	Distance to the Venue	No on map
NC	Adagio Vienna City	City centre	15 minutes (U1)	1
3	Alpha	City centre - Rathaus	20 minutes (U2 & U1)	2
5	Ambassador	City centre	15 minutes (U1)	3
4	Ananas	City centre - South-west	25 minutes (U4 & U1)	4
4	ARCOTEL Wimberger	City centre - West	25 minutes (U3 & U1)	5
4	Astoria	City centre	15 minutes (U1)	6
5	Bristol	City centre	15 minutes (U1)	7
4	Courtyard by Marriott Wien Messe	Venue & Messe area	15 minutes (U2 & U1)	8
NC	De France	City centre - Rathaus	20 minutes (U2 & U1)	9
4	Der Wilhelmshof	Venue & Messe area	10 minutes (U1)	10
4	Donauzentrum	Venue	8 minutes (U1)	11
4	Europa Wien	City centre	15 minutes (U1)	12
4	Falkensteiner Hotel Am Schottenfeld	City centre - West	30 minutes (U3 or U2 & U1)	13
NC	Fleming's Deluxe Hotel Wien City	City centre - Rathaus	20 minutes (U2 & U1)	14
4	Fleming's Hotel Wien Westbanhof	City centre - West	25 minutes (U3 & U1)	15
4	Graben Hotel	City centre	15 minutes (U1)	16
5	Grand Hotel	City centre	15 minutes (U1)	17
NC	Hilton Vienna	City centre - Stadtpark	20 minutes (U4 & U1)	18
4	Hilton Vienna Danube Waterfront	Venue & Messe area	15 minutes (U2 & U1)	19
NC	Hilton Vienna Plaza	City centre - Rathaus	20 minutes (U2 & U1)	20
4	Hotel Am Konzerthaus	City centre - Stadtpark	25 minutes (U4 & U1)	21
NC	Ibis Styles Wien City	City centre - Rathaus	40 minutes (U6, U4 & U1)	22
3	Ibis Wien City	City centre - South-west	30 minutes (U4 & U1)	23
3	Ibis Wien Mariahilf	City centre - West	35 minutes (U3 & U1)	24
3	Ibis Wien Messe	Venue & Messe area	10 minutes (U1)	25
NC	Imperial Riding School Renaissance	City centre - Belvedere	30 minutes (S-Bahn & U1)	26
4	InterCityHotel Wien	City centre - West	25 minutes (U3 & U1)	27
NC	InterContinental	City centre - Stadtpark	20 minutes (U4 & U1)	28
4	Johan Strauss	City centre	15 minutes (U1)	29
4	Kummer	City centre - West	20 minutes (U3 & U1)	30
5	Le Meridien Vienna	City centre	15 minutes (U1)	31
4	Lindner Hotel Am Belvedere	City centre - Belvedere	30 minutes (S-Bahn & U1)	32
NC	Meliá Vienna	Venue	3 minutes walking distance	33
4	Mercure Grand Hotel Biedermeier	City centre - Stadtpark	30 minutes (U3 & U1)	34
4	Mercure Secession Wien	City centre	15 minutes (U1)	35
4	Mercure Wien City	City centre	15 minutes (U1)	36
4	Mercure Wien Josefshof	City centre - Rathaus	20 minutes (U2 & U1)	37
4	Mercure Wien Westbahnhof	City centre - West	25 minutes (U3 & U1)	38
NC	Mercure Wien Zentrum	City centre	15 minutes (U1)	39
NC	Motel One Wien-Prater	Venue & Messe area	15 minutes (U2 & U1)	40
4	NH Danube City	Venue	12 minutes walking distance	41
4	Novotel Wien City	City centre	15 minutes (U1)	42
5	Palais Hansen Kempinski	City centre - Rathaus	20 minutes (U2 & U1)	43
4	Park Inn by Radisson Uno City	Venue	10 minutes walking distance	44
NC	pentahotel Vienna	City centre - South-west	30 minutes (U4 & U1)	45
5	Radisson BLU Style	City centre	20 minutes (U3 & U1)	46
4	Rathauspark	City centre - Rathaus	20 minutes (U2 & U1)	47
4	Regina	City centre - Rathaus	20 minutes (U2 & U1)	48
5	Ring Hotel	City centre	15 minutes (U1)	49
4	Royal Hotel	City centre	15 minutes (U1)	50
4	Savoyen	City centre - Belvedere	30 minutes (S-Bahn & U1)	51
5	Sofitel Vienna Stephansdom	City centre	15 minutes (U1)	52
5	Steigenberger Hotel Herrenhof	City centre	20 minutes (U3 & U1)	53
	Vienna Marriott Hotel	City centre - Stadtpark	25 minutes (U4 & U1)	54
5				





#### **ABSTRACTS**

Notification of abstract acceptance/rejection: March 23, 2016

#### **REGISTRATIONS**

Late: April 27, 2016

Blank - Name list: May 4, 2016

Onsite: from April 28, 2016



### **Next ERA-EDTA Congresses**









Actively be part of the largest and most important Nephrological Society in Europe.

Receive its journals NDT (Nephrology Dialysis Transplantation) and CKJ (Clinical Kidney Journal - NOW OPEN ACCESS!), the most important nephrological journals in Europe.

Participate in its annual congresses, major events attended by nephrologists from all over the world. Almost 8,200 delegates participated in the last ERA-EDTA Congress (London, UK - May 28-31, 2015). ERA-EDTA members can take advantage of extremely low early preregistration fees.

ERA-EDTA started its Fellowship Programme in 2006. Up to now, more than 170 fellowships have been granted.

The ERA-EDTA Research Programme is an initiative launched in 2009, 3 calls took place till now. Should you wish to know which projects have been granted from 2009, please visit the Research Programme section of our website www.era-edta.org.

ERA-EDTA has a diverse and expanding programme of CME Courses throughout Europe. In 2015, 28 events have been organised in many different countries. ERA-EDTA members receive free access to a selection of these courses directly online.



The ERA-EDTA Registry (www. era-edta-reg.org) collects, analyses, distributes, reports data on renal replacement therapy in Europe, at congresses, on journals and on a dedicated website. It also teaches CMEs and trains fellows.

ERBP (European Renal Best Practice - www.european-renal-best-practice.org): defines the future of European nephrology guidance.





# ERA-EDTA for You

Leading European Nephrology

Close collaboration between ERA-EDTA and "The Lancet" and "The Lancet Diabetes & Endocrinology". Issues of both journals were devoted to kidney diseases and were published in conjunction with the ERA-EDTA Congresses in Amsterdam (2014) and London

(2015). Two sessions have been organised jointly both at the 2014 and 2015 meetings. The collaboration has been confirmed for 2016 with a special renal issue scheduled for May 2016 and two symposia at the ERA-EDTA Congress in Vienna).

Joint scientific symposia

Co-hosted by the
European Reral Association-European Dialysis and Transplant
Association, The Lancet, and The Lancet Diabeter & Endocrinology

Cheld A DETA Company 2015, Look of the Name CE 1. THE LANCET THE LANCET THE LANCET CONTROL OF THE NAME CE 1. CHARGE OF THE LANCE TO CONTROL OF THE

The ERA-EDTA initiatives for young nephrologists include a number of grants of various kinds: Travel Grants to present free communications or posters at the annual congress, Travel Grants to attend CME Courses, further grants assigned through the National Societies of Nephrology based in European countries.



13

ERA-EDTA has created an educational online journal — NDT-Educational — which is one of the most successful in the nephrological world, with over 100,000 downloads per year.

Literature Review is another feature that NDT-Educational offers to its registered users. Experts select and comment the most interesting recent articles related to the various nephrology fields.

ERA-EDTA cooperates with other major Societies of Nephrology and other medical specialties:

special ERA-EDTA sessions are organized at the ASN, ISN, ESPN, ESC, etc.

14

ERA-EDTA has created specific Working Groups to encourage research, communication of knowledge, teaching and to participate in education programmes.

ERA-EDTA gives more than 1,300 free online subscriptions to NDT and CKJ to developing countries all over the world through the HINARI

programme; furthermore members living in developing countries all over the world pay an extremely low annual membership fee.

All ERA-EDTA members who are younger than 40 years of age can become part of the Young Nephrologists' Platform (YNP). This

The make white the DR is to have been good and the DR is to acc in the Standard growth of t

new initiative will allow young members to actively participate in the scientific life of the Society.

Peedback Questionnaire 2014

Reg at the improvement of the period of the

www.era-edta.org



# Österreichische Gesellschaft für Nephrologie

# Living with kidney disease in AUSTria


means that


The chances for early identification of CKD and timely intervention to stop progression are increasing. The Austrian Society of Nephrology has launched the "60/20 initiative", which implies that measurement of eGFR and testing for albuminuria will be offered to all individuals at risk for CKD and be included in routine health examinations. The program will ensure that every patient diagnosed with an eGFR below 60 ml/ min/1.73 m<sup>2</sup> and CKD will receive diagnostic work-up and appropriate management and, if indicated, will

be seen by a nephrologist.

Every patient with an eGFR below 20 ml/min/1.73 m<sup>2</sup> will be taken care of in a specialised nephrology unit in order to ensure optimal preparation for renal replacement therapy. The Austrian Society of Nephrology has developed standardised material to ensure uniform patient information and to enable a shared decision between patients and doctors on treatment modality selection.


Every suitable patient has a good chance of receiving a kidney allograft in due time. In 2014, a total of 446 renal transplantations (53 per million population) were performed, an all-time high. More than half of the 9000 Austrians on renal replacement therapy live with a functioning renal allograft.





The Austrian Society of Nephrology (ÖGN) represents 270 nephrologists and 79 facilities specialised in the management of patients suffering from all acute and chronic kidney diseases. Our Society's primary intention is to ensure that every patient has access to all modern and up-to-date diagnostic and therapeutic options in nephrological care. This requires increased public awareness of kidney diseases and specifically amongst policy makers in order to generate financial and staff resources for diagnostic and therapeutic facilities and research. To achieve this goal, continuous

#### NEPHROLOGY AND TRANSPLANT CENTERS



education is required in all aspects of our field for our members, students, trainees and all other health care professionals involved in the management of patients with kidney disease. The ÖGN supports and appreciates the scientific efforts and activity of its members, which is also reflected by the active participation of speakers from our society at the forthcoming 53rd ERA-EDTA congress in Vienna.

The Society is particularly proud of its Austrian Dialysis and Transplant Registry (ÖDTR), which has collected data of all Austrian patients entering renal replacement therapy from 1965. The voluntary registry provides an invaluable source of data for epidemiological research and clinical quality improvement.

The ÖGN cordially invites you to attend the forthcoming 53rd ERA-EDTA congress in Vienna. Enjoy not only an outstanding scientific program but also the beauty and culture of Vienna and Austria.

ÖGN website: www.niere-hochdruck.at

Contact: oean@vlkh.net


Registry website: www.nephro.at


# Oxford University Press Book Club




# Exclusive 35% discount for ERA-EDTA members

visit http://www.oup.com/uk/sale/eraedta





























Become a member and start to network **now!** 








# WHY SHOULD YOU BECOME AN ERA-EDTA INTENTAL STATEMENT OF THE PROPERTY OF THE PR

Leading European Nephrology







WWW.ERA-EDTA2016.0RG